Bayer's Metastasis in Cancer
Executive Summary
Three years ago, Bayer AG's diagnostics business formed a collaboration with the diagnostics subsidiary of OSI Pharmaceuticals Inc. (then Oncogene Sciences Diagnostics). The relationship was progressing smoothly, so it's no wonder that OSI turned to Bayer first when it decided to divest the diagnostics business this fall. Bayer quickly snapped it up for $11 million. For that price, Bayer getes one of the oldest tumor marker companies. The deal fits in with Bayer's long-term interest in cancer genomics and the company's collaboration has already produced one success--the introduction of an automated serum assay for Her-2/neu receptors.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.